Skip to main content
HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
Home
Table of Contents
Test, Evaluate, Monitor
Treatment-Naive Patients
Treatment-Experienced Patients
Unique & Key Populations
About the Guidance
Home
Table of Contents
Introduction
Methods
Methods Table 1
Methods Table 2
Methods Table 3 Abbreviations
References
Test, Evaluate, Monitor
Testing and Linkage to Care
When and in Whom
Cost, Reimbursement, and Cost-Effectiveness
Monitoring
HCV Resistance
Treatment-Naive
Simplified: No Cirrhosis
Simplified: Comp. Cirrhosis
Decompensated Cirrhosis
Genotype 1
GT1a: No Cirrhosis
GT1a: Compensated
GT1b: No Cirrhosis
GT1b: Compensated
Genotype 2
GT2 : No Cirrhosis
GT2 : Compensated
Genotype 3
GT3 : No Cirrhosis
GT3 : Compensated
Genotype 4
GT4 : No Cirrhosis
GT4 : Compensated
Genotype 5 or 6
Treatment-Experienced
Genotype 1
GT1a : P/R : No Cirrhosis
GT1a : P/R : Compensated
GT1b : P/R : No Cirrhosis
GT1b : P/R : Compensated
GT1 : NS3 : No Cirrhosis
GT1 : NS3 : Compensated
GT1 : Non-NS5A : No Cirrhosis
GT1 : Non-NS5A : Compensated
GT1 : NS5A
All GT: G/P
All GT: SOF/VEL/VOX
Genotype 2
GT2 : P/R : No Cirrhosis
GT2 : P/R : Compensated
GT2 : DAA
All GT: G/P
All GT: SOF/VEL/VOX
Genotype 3
GT3 : P/R : No Cirrhosis
GT3 : P/R : Compensated
GT3 : DAA
All GT: G/P
All GT: SOF/VEL/VOX
Genotype 4
GT4 : P/R : No Cirrhosis
GT4 : P/R : Compensated
GT4 : DAA
All GT: G/P
All GT: SOF/VEL/VOX
Genotype 5 or 6
GT 5 or 6 : P/R
GT 5 or 6 : DAA
All GT: G/P
All GT: SOF/VEL/VOX
Decompensated Cirrhosis
Unique & Key Populations
HIV/HCV Coinfection
Decompensated Cirrhosis
Post Liver Transplant
Organs from HCV-Viremic Donors
Renal Impairment
Kidney Transplant
Acute Infection
HCV in Pregnancy
HCV in Children
PWID, MSM & Corrections
People Who Inject Drugs
Men Who Have Sex With Men
Correctional Settings
About
Announcements
Organizations
Panel
Disclosures
Process
Citing and Permissions
Survey
Website Policies
Contact
You are here
Home
›
Treatment-Experienced
›
GT1
›
Summary
Summary: NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosis
Recommended and alternative regimens listed by evidence level and alphabetically for:
NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosis
a
RECOMMENDED
DURATION
RATING
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg)
12 weeks
I, A
ALTERNATIVE
DURATION
RATING
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)
b
except NS3/4 protease inhibitor inclusive DAA combination regimens
16 weeks
IIa, B
a
For
decompensated cirrhosis
, please refer to the appropriate section.
b
Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.
Last update:
November 6, 2019
Previous Page
Next Page
Top